MX2018009867A - Metodos que comprenden una dosificacion intermitente fija de cediranib. - Google Patents

Metodos que comprenden una dosificacion intermitente fija de cediranib.

Info

Publication number
MX2018009867A
MX2018009867A MX2018009867A MX2018009867A MX2018009867A MX 2018009867 A MX2018009867 A MX 2018009867A MX 2018009867 A MX2018009867 A MX 2018009867A MX 2018009867 A MX2018009867 A MX 2018009867A MX 2018009867 A MX2018009867 A MX 2018009867A
Authority
MX
Mexico
Prior art keywords
cediranib
administration
methods
composition
consecutive days
Prior art date
Application number
MX2018009867A
Other languages
English (en)
Inventor
Barry Simon
Kendrew Jane
Ho Tony
Robert Wedge Stephen
Percy Ivy Susan
KOHN Elise
Min LEE Jung-
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2018009867A publication Critical patent/MX2018009867A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se divulgan métodos que comprenden ciclos repetidos de administración de una composición que comprende cediranib de acuerdo con un patrón posológico intermitente fijo que comprende la administración de una cantidad eficaz de la composición que comprende cediranib en uno o más días consecutivos de un ciclo seguidos por uno o más días consecutivos de descanso en los cuales no se administra dicha composición, y se pueden utilizar como monoterapia o pueden comprender la administración de una o más terapias o fármacos asociados y se pueden utilizar en la terapia combinada. Tales métodos pueden producir un efecto antiangiogénico y/o reductor de la permeabilidad vascular, tratar al menos un estado patológico asociado con la angiogénesis, reducir la dosis total de cediranib requerida para proporcionar una inhibición de VEGF eficaz, reducir los eventos adversos y toxicidad debidos a la administración de cediranib, mantener la actuación sobre la ruta de VEGF a pesar de la reducción de las dosis totales de cediranib, y/o incrementar la reparación de tejido sano, no canceroso durante el tratamiento de cáncer utilizando terapias combinadas.
MX2018009867A 2016-02-15 2017-02-14 Metodos que comprenden una dosificacion intermitente fija de cediranib. MX2018009867A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662295421P 2016-02-15 2016-02-15
PCT/US2017/017804 WO2017142871A1 (en) 2016-02-15 2017-02-14 Methods comprising fixed intermittent dosing of cediranib

Publications (1)

Publication Number Publication Date
MX2018009867A true MX2018009867A (es) 2019-05-27

Family

ID=59625551

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018009867A MX2018009867A (es) 2016-02-15 2017-02-14 Metodos que comprenden una dosificacion intermitente fija de cediranib.
MX2023007826A MX2023007826A (es) 2016-02-15 2018-08-14 Metodos que comprenden una dosificacion intermitente fija de cediranib.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023007826A MX2023007826A (es) 2016-02-15 2018-08-14 Metodos que comprenden una dosificacion intermitente fija de cediranib.

Country Status (16)

Country Link
US (1) US20210322415A1 (es)
EP (2) EP4071174A1 (es)
JP (2) JP6865762B2 (es)
KR (1) KR102830910B1 (es)
CN (1) CN109073650A (es)
AU (1) AU2017221268B2 (es)
CA (1) CA3014674C (es)
DK (1) DK3417294T3 (es)
ES (1) ES2906813T3 (es)
HU (1) HUE058114T2 (es)
MA (1) MA44251A (es)
MX (2) MX2018009867A (es)
PL (1) PL3417294T3 (es)
RU (1) RU2740849C2 (es)
TW (1) TWI827530B (es)
WO (1) WO2017142871A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202444417A (zh) 2017-05-09 2024-11-16 美商提薩羅有限公司 治療癌症的組合療法
KR20200005662A (ko) 2017-05-18 2020-01-15 테사로, 인코포레이티드 암을 치료하기 위한 조합 요법
MX2020003770A (es) 2017-09-30 2020-07-29 Tesaro Inc Terapias de combinacion para tratar cancer.
EA202090655A1 (ru) * 2017-10-06 2020-12-07 Тесаро, Инк. Комбинированные терапевтические средства и их применение

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
PT1154774E (pt) 1999-02-10 2005-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de angiogenese
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
AU2003226408B2 (en) * 2002-04-15 2007-06-14 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
JP2008514576A (ja) * 2004-09-27 2008-05-08 アストラゼネカ アクチボラグ Ａｚｄ２１７１およびイマチニブを含む癌組合せ療法
US20090035317A1 (en) * 2007-01-12 2009-02-05 Daugherty Patrick S Peptides binding to vascular endothelial growth factor
AU2009215375A1 (en) * 2008-02-21 2009-08-27 Astrazeneca Ab Combination therapy 238
CN102307475A (zh) * 2009-02-04 2012-01-04 彼帕科学公司 用与生长因子抑制剂组合的parp抑制剂治疗肺癌
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
WO2013070976A1 (en) * 2011-11-08 2013-05-16 Intellikine, Llc Treatment regimens using multiple pharmaceutical agents
JP6184423B2 (ja) * 2012-05-18 2017-08-23 大日本住友製薬株式会社 カルボン酸化合物
CA2889182A1 (en) * 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
KR20230076867A (ko) * 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
NO2714752T3 (es) * 2014-05-08 2018-04-21
EP4245376A3 (en) * 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof

Also Published As

Publication number Publication date
AU2017221268A1 (en) 2018-08-30
WO2017142871A8 (en) 2018-06-14
JP2021105039A (ja) 2021-07-26
CA3014674C (en) 2024-06-18
ES2906813T3 (es) 2022-04-20
HUE058114T2 (hu) 2022-07-28
KR102830910B1 (ko) 2025-07-04
CA3014674A1 (en) 2017-08-24
JP6865762B2 (ja) 2021-04-28
US20210322415A1 (en) 2021-10-21
MA44251A (fr) 2018-12-26
EP3417294B8 (en) 2022-05-04
AU2017221268B2 (en) 2024-02-15
CN109073650A (zh) 2018-12-21
EP3417294A1 (en) 2018-12-26
WO2017142871A1 (en) 2017-08-24
EP3417294B1 (en) 2021-12-01
RU2740849C2 (ru) 2021-01-21
RU2018131377A (ru) 2020-03-17
EP4071174A1 (en) 2022-10-12
KR20180125456A (ko) 2018-11-23
JP2019504860A (ja) 2019-02-21
TWI827530B (zh) 2024-01-01
MX2023007826A (es) 2023-07-07
DK3417294T3 (da) 2022-02-21
EP3417294A4 (en) 2019-08-14
PL3417294T3 (pl) 2022-05-09
JP7271594B2 (ja) 2023-05-11
TW201906610A (zh) 2019-02-16
RU2018131377A3 (es) 2020-06-02

Similar Documents

Publication Publication Date Title
CL2023000846A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2017012991A (es) Combinaciones de amisulprida y otro antiemetico para tratar nausea y vomito.
MX2015013355A (es) Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer.
BR112017011536A2 (pt) terapias de combinação
BR112017014067A2 (pt) composição para tratar doenças relacionadas a il-6
JOP20160092B1 (ar) علاج البيتا ثلاسيميا باستخدام مصطبة لجائنية
NI201400104A (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
ECSP14012676A (es) Compuestos de carbamato y preparación y uso de los mismos
CO2017007662A2 (es) Terapias de combinación para el tratamiento de cánceres
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
MX380767B (es) Métodos para reducir el riesgo cardiovascular.
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
MX2017000628A (es) Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia.
ECSP109969A (es) Terapia especifica y medicamento que usan ligando de integrina para tratar cancer
MX2018009867A (es) Metodos que comprenden una dosificacion intermitente fija de cediranib.
MX381440B (es) Composicion farmaceutica para tratar colitis ulcerativa.
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
AR103118A1 (es) Tratamientos médicos basados en anamorelina
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2017008486A (es) Combinaciones del inhibidor de tirosina cinasa de bruton (btk) y regimenes de dosificacion.
PH12017502046A1 (en) Salts and prodrugs of 1-methyl-d-tryptophan
MX2018013873A (es) Irinotecan nanoliposomico para usarse en el tratamiento del cancer de pulmon de celulas pequeñas.
EA201692278A1 (ru) Комбинации формотерола и будесонида для лечения хобл